September 15th 2025
Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.
September 15th 2025
September 14th 2025
September 12th 2025
September 11th 2025
September 11th 2025
September 10th 2025
September 10th 2025
July 13th 2025